{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:30:39Z","timestamp":1779211839493,"version":"3.51.4"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82171347"],"award-info":[{"award-number":["No. 82171347"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-01863-2","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:17:28Z","timestamp":1738779448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Circadian rhythm related genes signature in glioma for drug resistance prediction: a comprehensive analysis integrating transcriptomics and machine learning"],"prefix":"10.1007","volume":"16","author":[{"given":"Junbo","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxing","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangwang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaxue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaohong","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gelei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"issue":"7717","key":"1863_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41586-018-0389-3","volume":"560","author":"JH Lee","year":"2018","unstructured":"Lee JH, Lee JE, Kahng JY, Kim SH, Park JS, Yoon SJ, et al. Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature. 2018;560(7717):243\u20137.","journal-title":"Nature"},{"issue":"3","key":"1863_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11060-017-2379-y","volume":"134","author":"K Ludwig","year":"2017","unstructured":"Ludwig K, Kornblum HI. Molecular markers in glioma. J Neurooncol. 2017;134(3):505\u201312.","journal-title":"J Neurooncol"},{"issue":"5","key":"1863_CR3","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.soncn.2018.10.001","volume":"34","author":"ME Davis","year":"2018","unstructured":"Davis ME. Epidemiology and overview of gliomas. Semin Oncol Nurs. 2018;34(5):420\u20139.","journal-title":"Semin Oncol Nurs"},{"issue":"8","key":"1863_CR4","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231\u201351.","journal-title":"Neuro Oncol"},{"key":"1863_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/1471-2407-10-305","volume":"10","author":"JX Cheng","year":"2010","unstructured":"Cheng JX, Liu BL, Zhang X, Lin W, Zhang YQ, Liu WP, et al. Health-related quality of life in glioma patients in China. BMC Cancer. 2010;10:305.","journal-title":"BMC Cancer"},{"issue":"1","key":"1863_CR6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1186\/s40064-016-2578-6","volume":"5","author":"ME Robertson","year":"2016","unstructured":"Robertson ME, McSherry F, Herndon JE, Peters KB. Insomnia and its associations in patients with recurrent glial neoplasms. Springerplus. 2016;5(1):823.","journal-title":"Springerplus"},{"issue":"1","key":"1863_CR7","first-page":"48","volume":"8","author":"MS Jeon","year":"2021","unstructured":"Jeon MS, Dhillon HM, Koh ES, Nowak AK, Hovey E, Descallar J, et al. Exploring sleep disturbance among adults with primary or secondary malignant brain tumors and their caregivers. Neurooncol Pract. 2021;8(1):48\u201359.","journal-title":"Neurooncol Pract"},{"key":"1863_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2020.101409","volume":"56","author":"MP Mogavero","year":"2021","unstructured":"Mogavero MP, DelRosso LM, Fanfulla F, Bruni O, Ferri R. Sleep disorders and cancer: state of the art and future perspectives. Sleep Med Rev. 2021;56: 101409.","journal-title":"Sleep Med Rev"},{"key":"1863_CR9","doi-asserted-by":"crossref","unstructured":"Walker WH, 2nd, Borniger JC. Molecular mechanisms of cancer-induced sleep disruption. Int J Mol Sci. 2019;20(11):2780.","DOI":"10.3390\/ijms20112780"},{"key":"1863_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.sleep.2019.02.018","volume":"58","author":"K Schieber","year":"2019","unstructured":"Schieber K, Niecke A, Geiser F, Erim Y, Bergelt C, Buttner-Teleaga A, et al. The course of cancer-related insomnia: don\u2019t expect it to disappear after cancer treatment. Sleep Med. 2019;58:107\u201313.","journal-title":"Sleep Med"},{"issue":"1","key":"1863_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1158\/1078-0432.CCR-16-0574","volume":"23","author":"BL Andersen","year":"2017","unstructured":"Andersen BL, Goyal NG, Westbrook TD, Bishop B, Carson WE 3rd. Trajectories of stress, depressive symptoms, and immunity in cancer survivors: diagnosis to 5 years. Clin Cancer Res. 2017;23(1):52\u201361.","journal-title":"Clin Cancer Res"},{"issue":"3 Suppl 1","key":"1863_CR12","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.amepre.2013.10.033","volume":"46","author":"SM Gapstur","year":"2014","unstructured":"Gapstur SM, Diver WR, Stevens VL, Carter BD, Teras LR, Jacobs EJ. Work schedule, sleep duration, insomnia, and risk of fatal prostate cancer. Am J Prev Med. 2014;46(3 Suppl 1):S26-33.","journal-title":"Am J Prev Med"},{"issue":"1","key":"1863_CR13","doi-asserted-by":"publisher","first-page":"18317","DOI":"10.1038\/s41598-022-21879-w","volume":"12","author":"J Chen","year":"2022","unstructured":"Chen J, Chen N, Huang T, Huang N, Zhuang Z, Liang H. Sleep pattern, healthy lifestyle and colorectal cancer incidence. Sci Rep. 2022;12(1):18317.","journal-title":"Sci Rep"},{"issue":"2","key":"1863_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s11060-019-03373-y","volume":"146","author":"MCM Peeters","year":"2020","unstructured":"Peeters MCM, Dirven L, Koekkoek JAF, Gortmaker EG, Fritz L, Vos MJ, et al. Prediagnostic symptoms and signs of adult glioma: the patients\u2019 view. J Neurooncol. 2020;146(2):293\u2013301.","journal-title":"J Neurooncol"},{"issue":"4","key":"1863_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13598","volume":"31","author":"A Borbely","year":"2022","unstructured":"Borbely A. The two-process model of sleep regulation: beginnings and outlook. J Sleep Res. 2022;31(4): e13598.","journal-title":"J Sleep Res"},{"issue":"3","key":"1863_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nrg.2016.150","volume":"18","author":"JS Takahashi","year":"2017","unstructured":"Takahashi JS. Transcriptional architecture of the mammalian circadian clock. Nat Rev Genet. 2017;18(3):164\u201379.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"1863_CR17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13073-019-0704-0","volume":"11","author":"F Rijo-Ferreira","year":"2019","unstructured":"Rijo-Ferreira F, Takahashi JS. Genomics of circadian rhythms in health and disease. Genome Med. 2019;11(1):82.","journal-title":"Genome Med"},{"key":"1863_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18050938","author":"A Charrier","year":"2017","unstructured":"Charrier A, Olliac B, Roubertoux P, Tordjman S. Clock genes and altered sleep-wake rhythms: their role in the development of psychiatric disorders. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18050938.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1863_CR19","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41568-020-0291-9","volume":"20","author":"K Kinouchi","year":"2020","unstructured":"Kinouchi K, Sassone-Corsi P. Metabolic rivalry: circadian homeostasis and tumorigenesis. Nat Rev Cancer. 2020;20(11):645\u201361.","journal-title":"Nat Rev Cancer"},{"key":"1863_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112756","author":"J De La Cruz Minyety","year":"2021","unstructured":"De La Cruz Minyety J, Shuboni-Mulligan DD, Briceno N, Young D Jr, Gilbert MR, Celiku O, et al. Association of circadian clock gene expression with glioma tumor microenvironment and patient survival. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13112756.","journal-title":"Cancers (Basel)."},{"issue":"3","key":"1863_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1158\/2159-8290.CD-19-0400","volume":"10","author":"P Chen","year":"2020","unstructured":"Chen P, Hsu WH, Chang A, Tan Z, Lan Z, Zhou A, et al. Circadian regulator CLOCK recruits immune-suppressive microglia into the GBM tumor microenvironment. Cancer Discov. 2020;10(3):371\u201381.","journal-title":"Cancer Discov"},{"issue":"1","key":"1863_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12967-019-1880-9","volume":"17","author":"WH Chang","year":"2019","unstructured":"Chang WH, Lai AG. Timing gone awry: distinct tumour suppressive and oncogenic roles of the circadian clock and crosstalk with hypoxia signalling in diverse malignancies. J Transl Med. 2019;17(1):132.","journal-title":"J Transl Med"},{"issue":"3","key":"1863_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12988","volume":"54","author":"Z Wang","year":"2021","unstructured":"Wang Z, Su G, Dai Z, Meng M, Zhang H, Fan F, et al. Circadian clock genes promote glioma progression by affecting tumour immune infiltration and tumour cell proliferation. Cell Prolif. 2021;54(3): e12988.","journal-title":"Cell Prolif"},{"key":"1863_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.719631","volume":"12","author":"S Bevinakoppamath","year":"2021","unstructured":"Bevinakoppamath S, Ramachandra SC, Yadav AK, Basavaraj V, Vishwanath P, Prashant A. Understanding the emerging link between circadian rhythm, Nrf2 pathway, and breast cancer to overcome drug resistance. Front Pharmacol. 2021;12: 719631.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1863_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12803","volume":"73","author":"L He","year":"2022","unstructured":"He L, Fan Y, Zhang Y, Tu T, Zhang Q, Yuan F, et al. Single-cell transcriptomic analysis reveals circadian rhythm disruption associated with poor prognosis and drug-resistance in lung adenocarcinoma. J Pineal Res. 2022;73(1): e12803.","journal-title":"J Pineal Res"},{"issue":"4","key":"1863_CR26","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00415-017-8695-5","volume":"265","author":"JT Miyauchi","year":"2018","unstructured":"Miyauchi JT, Tsirka SE. Advances in immunotherapeutic research for glioma therapy. J Neurol. 2018;265(4):741\u201356.","journal-title":"J Neurol"},{"key":"1863_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.02.002","volume":"476","author":"S Xu","year":"2020","unstructured":"Xu S, Tang L, Li X, Fan F, Liu Z. Immunotherapy for glioma: current management and future application. Cancer Lett. 2020;476:1\u201312.","journal-title":"Cancer Lett"},{"issue":"2","key":"1863_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0748730417696788","volume":"32","author":"EA Slat","year":"2017","unstructured":"Slat EA, Sponagel J, Marpegan L, Simon T, Kfoury N, Kim A, et al. Cell-intrinsic, Bmal1-dependent circadian regulation of temozolomide sensitivity in glioblastoma. J Biol Rhythms. 2017;32(2):121\u20139.","journal-title":"J Biol Rhythms"},{"issue":"2","key":"1863_CR29","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1074\/jbc.RA118.004942","volume":"294","author":"C Katamune","year":"2019","unstructured":"Katamune C, Koyanagi S, Hashikawa KI, Kusunose N, Akamine T, Matsunaga N, et al. Mutation of the gene encoding the circadian clock component PERIOD2 in oncogenic cells confers chemoresistance by up-regulating the Aldh3a1 gene. J Biol Chem. 2019;294(2):547\u201358.","journal-title":"J Biol Chem"},{"issue":"1","key":"1863_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10555-021-09997-9","volume":"41","author":"L Barthel","year":"2022","unstructured":"Barthel L, Hadamitzky M, Dammann P, Schedlowski M, Sure U, Thakur BK, et al. Glioma: molecular signature and crossroads with tumor microenvironment. Cancer Metastasis Rev. 2022;41(1):53\u201375.","journal-title":"Cancer Metastasis Rev"},{"key":"1863_CR31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/978-3-030-49270-0_11","volume":"1273","author":"AP Cole","year":"2020","unstructured":"Cole AP, Hoffmeyer E, Chetty SL, Cruz-Cruz J, Hamrick F, Youssef O, et al. Microglia in the brain tumor microenvironment. Adv Exp Med Biol. 2020;1273:197\u2013208.","journal-title":"Adv Exp Med Biol"},{"key":"1863_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cells10030484","author":"A Goenka","year":"2021","unstructured":"Goenka A, Tiek D, Song X, Huang T, Hu B, Cheng SY. The many facets of therapy resistance and tumor recurrence in glioblastoma. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10030484.","journal-title":"Cells"},{"key":"1863_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228476","author":"DP Radin","year":"2020","unstructured":"Radin DP, Tsirka SE. Interactions between tumor cells, neurons, and microglia in the glioma microenvironment. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21228476.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1863_CR34","doi-asserted-by":"publisher","first-page":"665","DOI":"10.7150\/thno.41692","volume":"11","author":"NH Boyd","year":"2021","unstructured":"Boyd NH, Tran AN, Bernstock JD, Etminan T, Jones AB, Gillespie GY, et al. Glioma stem cells and their roles within the hypoxic tumor microenvironment. Theranostics. 2021;11(2):665\u201383.","journal-title":"Theranostics"},{"issue":"5","key":"1863_CR35","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.trecan.2020.02.010","volume":"6","author":"M Butler","year":"2020","unstructured":"Butler M, Pongor L, Su YT, Xi L, Raffeld M, Quezado M, et al. MGMT status as a clinical biomarker in glioblastoma. Trends Cancer. 2020;6(5):380\u201391.","journal-title":"Trends Cancer"},{"key":"1863_CR36","doi-asserted-by":"crossref","unstructured":"Da Ros M, De Gregorio V, Iorio AL, Giunti L, Guidi M, de Martino M, et al. Glioblastoma chemoresistance: the double play by microenvironment and blood-brain barrier. Int J Mol Sci. 2018;19(10):2879.","DOI":"10.3390\/ijms19102879"},{"key":"1863_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107922","volume":"228","author":"F Lang","year":"2021","unstructured":"Lang F, Liu Y, Chou FJ, Yang C. Genotoxic therapy and resistance mechanism in gliomas. Pharmacol Ther. 2021;228: 107922.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1863_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1158\/1078-0432.CCR-13-1279","volume":"20","author":"J Liang","year":"2014","unstructured":"Liang J, Piao Y, Holmes L, Fuller GN, Henry V, Tiao N, et al. Neutrophils promote the malignant glioma phenotype through S100A4. Clin Cancer Res. 2014;20(1):187\u201398.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1863_CR39","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.it.2021.02.004","volume":"42","author":"W Xuan","year":"2021","unstructured":"Xuan W, Lesniak MS, James CD, Heimberger AB, Chen P. Context-dependent glioblastoma-macrophage\/microglia symbiosis and associated mechanisms. Trends Immunol. 2021;42(4):280\u201392.","journal-title":"Trends Immunol"},{"issue":"2","key":"1863_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112127","volume":"42","author":"L Pang","year":"2023","unstructured":"Pang L, Dunterman M, Xuan W, Gonzalez A, Lin Y, Hsu WH, et al. Circadian regulator CLOCK promotes tumor angiogenesis in glioblastoma. Cell Rep. 2023;42(2): 112127.","journal-title":"Cell Rep"},{"key":"1863_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13059-016-0881-8","volume":"17","author":"A Conesa","year":"2016","unstructured":"Conesa A, Madrigal P, Tarazona S, Gomez-Cabrero D, Cervera A, McPherson A, et al. A survey of best practices for RNA-seq data analysis. Genome Biol. 2016;17:13.","journal-title":"Genome Biol"},{"issue":"8","key":"1863_CR42","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1200\/JCO.2007.12.9791","volume":"26","author":"A Iasonos","year":"2008","unstructured":"Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364\u201370.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1863_CR43","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH, et al. Inference and analysis of cell-cell communication using Cell Chat. Nat Commun. 2021;12(1):1088.","journal-title":"Nat Commun"},{"issue":"9","key":"1863_CR44","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/cac2.12038","volume":"40","author":"D Liu","year":"2020","unstructured":"Liu D, Wu Y. Association of an anaplastic lymphoma kinase pathway signature with cell de-differentiation, neoadjuvant chemotherapy response, and recurrence risk in breast cancer. Cancer Commun (Lond). 2020;40(9):422\u201334.","journal-title":"Cancer Commun (Lond)"},{"issue":"2","key":"1863_CR45","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1517\/17425247.4.2.175","volume":"4","author":"AN Mamelak","year":"2007","unstructured":"Mamelak AN, Jacoby DB. Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv. 2007;4(2):175\u201386.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"1863_CR46","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00520-021-06476-3","volume":"30","author":"KD Willis","year":"2022","unstructured":"Willis KD, Ravyts SG, Lanoye A, Loughan AR. Sleep disturbance in primary brain tumor: prevalence, risk factors, and patient preferences. Support Care Cancer. 2022;30(1):741\u20138.","journal-title":"Support Care Cancer"},{"issue":"4","key":"1863_CR47","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1378\/chest.14-1617","volume":"147","author":"JC Levenson","year":"2015","unstructured":"Levenson JC, Kay DB, Buysse DJ. The pathophysiology of insomnia. Chest. 2015;147(4):1179\u201392.","journal-title":"Chest"},{"issue":"10","key":"1863_CR48","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s12276-021-00681-0","volume":"53","author":"Y Lee","year":"2021","unstructured":"Lee Y. Roles of circadian clocks in cancer pathogenesis and treatment. Exp Mol Med. 2021;53(10):1529\u201338.","journal-title":"Exp Mol Med"},{"issue":"1","key":"1863_CR49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13046-020-01639-2","volume":"39","author":"H Shen","year":"2020","unstructured":"Shen H, Cook K, Gee HE, Hau E. Hypoxia, metabolism, and the circadian clock: new links to overcome radiation resistance in high-grade gliomas. J Exp Clin Cancer Res. 2020;39(1):129.","journal-title":"J Exp Clin Cancer Res"},{"key":"1863_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.769592","volume":"11","author":"Y Shi","year":"2021","unstructured":"Shi Y, Wu M, Liu Y, Hu L, Wu H, Xie L, et al. ITGA5 predicts dual-drug resistance to temozolomide and bevacizumab in glioma. Front Oncol. 2021;11: 769592.","journal-title":"Front Oncol"},{"issue":"6","key":"1863_CR51","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s41590-022-01223-0","volume":"23","author":"S Lakshmanachetty","year":"2022","unstructured":"Lakshmanachetty S, Mitra SS. Mapping the tumor-infiltrating immune cells during glioblastoma progression. Nat Immunol. 2022;23(6):826\u20138.","journal-title":"Nat Immunol"},{"issue":"1","key":"1863_CR52","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41467-022-28372-y","volume":"13","author":"N Abdelfattah","year":"2022","unstructured":"Abdelfattah N, Kumar P, Wang C, Leu JS, Flynn WF, Gao R, et al. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nat Commun. 2022;13(1):767.","journal-title":"Nat Commun"},{"issue":"1","key":"1863_CR53","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","volume":"6","author":"T Tang","year":"2021","unstructured":"Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther. 2021;6(1):72.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1863_CR54","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","volume":"5","author":"MZ Jin","year":"2020","unstructured":"Jin MZ, Jin WL. The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020;5(1):166.","journal-title":"Signal Transduct Target Ther"},{"issue":"7946","key":"1863_CR55","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41586-022-05605-0","volume":"614","author":"C Wang","year":"2023","unstructured":"Wang C, Barnoud C, Cenerenti M, Sun M, Caffa I, Kizil B, et al. Dendritic cells direct circadian anti-tumour immune responses. Nature. 2023;614(7946):136\u201343.","journal-title":"Nature"},{"key":"1863_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.721897","volume":"9","author":"Z Chen","year":"2021","unstructured":"Chen Z, Zhuo S, He G, Tang J, Hao W, Gao WQ, et al. Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in gliomas. Front Cell Dev Biol. 2021;9: 721897.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1863_CR57","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12935-021-02089-2","volume":"21","author":"J Liu","year":"2021","unstructured":"Liu J, Geng X, Hou J, Wu G. New insights into M1\/M2 macrophages: key modulators in cancer progression. Cancer Cell Int. 2021;21(1):389.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"1863_CR58","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1080\/10717544.2018.1502839","volume":"25","author":"L Pang","year":"2018","unstructured":"Pang L, Zhu Y, Qin J, Zhao W, Wang J. Primary M1 macrophages as multifunctional carrier combined with PLGA nanoparticle delivering anticancer drug for efficient glioma therapy. Drug Deliv. 2018;25(1):1922\u201331.","journal-title":"Drug Deliv"},{"issue":"27","key":"1863_CR59","doi-asserted-by":"publisher","first-page":"eabl5165","DOI":"10.1126\/sciadv.abl5165","volume":"8","author":"X Ni","year":"2022","unstructured":"Ni X, Wu W, Sun X, Ma J, Yu Z, He X, et al. Interrogating glioma-M2 macrophage interactions identifies Gal-9\/Tim-3 as a viable target against PTEN-null glioblastoma. Sci Adv. 2022;8(27):eabl5165.","journal-title":"Sci Adv"},{"issue":"7","key":"1863_CR60","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1158\/1078-0432.CCR-18-1625","volume":"25","author":"BD Choi","year":"2019","unstructured":"Choi BD, Maus MV, June CH, Sampson JH. Immunotherapy for glioblastoma: adoptive T-cell strategies. Clin Cancer Res. 2019;25(7):2042\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1863_CR61","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11882-020-0896-9","volume":"20","author":"SN Waggoner","year":"2020","unstructured":"Waggoner SN. Circadian rhythms in immunity. Curr Allergy Asthma Rep. 2020;20(1):2.","journal-title":"Curr Allergy Asthma Rep"},{"key":"1863_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.694633","volume":"9","author":"S Xu","year":"2021","unstructured":"Xu S, Tang L, Liu Z, Yang K, Cheng Q. Bioinformatic analyses identify a prognostic autophagy-related long non-coding RNA signature associated with immune microenvironment in diffuse gliomas. Front Cell Dev Biol. 2021;9: 694633.","journal-title":"Front Cell Dev Biol"},{"key":"1863_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232213722","author":"V Jerigova","year":"2022","unstructured":"Jerigova V, Zeman M, Okuliarova M. Circadian disruption and consequences on innate immunity and inflammatory response. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232213722.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1863_CR64","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1158\/0008-5472.CAN-05-3773","volume":"66","author":"PE Fecci","year":"2006","unstructured":"Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66(6):3294\u2013302.","journal-title":"Cancer Res"},{"key":"1863_CR65","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3389\/fimmu.2013.00116","volume":"4","author":"DA Wainwright","year":"2013","unstructured":"Wainwright DA, Dey M, Chang A, Lesniak MS. Targeting Tregs in malignant brain cancer: overcoming IDO. Front Immunol. 2013;4:116.","journal-title":"Front Immunol"},{"key":"1863_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.679425","volume":"12","author":"A Ghouzlani","year":"2021","unstructured":"Ghouzlani A, Kandoussi S, Tall M, Reddy KP, Rafii S, Badou A. Immune checkpoint inhibitors in human glioma microenvironment. Front Immunol. 2021;12: 679425.","journal-title":"Front Immunol"},{"key":"1863_CR67","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20200520","author":"G Wu","year":"2020","unstructured":"Wu G, Song X, Liu J, Li S, Gao W, Qiu M, et al. Expression of CD44 and the survival in glioma: a meta-analysis. 2020. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20200520."},{"key":"1863_CR68","doi-asserted-by":"publisher","first-page":"1086280","DOI":"10.3389\/fimmu.2023.1086280","volume":"14","author":"H Zhang","year":"2023","unstructured":"Zhang H, Cao H, Luo H, Zhang N, Wang Z, Dai Z, et al. RUNX1\/CD44 axis regulates the proliferation, migration, and immunotherapy of gliomas: a single-cell sequencing analysis. Front Immunol. 2023;14:1086280.","journal-title":"Front Immunol"},{"issue":"9","key":"1863_CR69","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/neuonc\/nox050","volume":"19","author":"M Vitucci","year":"2017","unstructured":"Vitucci M, Irvin DM, McNeill RS, Schmid RS, Simon JM, Dhruv HD, et al. Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma. Neuro Oncol. 2017;19(9):1237\u201347.","journal-title":"Neuro Oncol"},{"key":"1863_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.933973","volume":"13","author":"JH Bao","year":"2022","unstructured":"Bao JH, Lu WC, Duan H, Ye YQ, Li JB, Liao WT, et al. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas. Front Immunol. 2022;13: 933973.","journal-title":"Front Immunol"},{"issue":"2","key":"1863_CR71","doi-asserted-by":"publisher","first-page":"zcab018","DOI":"10.1093\/narcan\/zcab018","volume":"3","author":"A Sule","year":"2021","unstructured":"Sule A, Van Doorn J, Sundaram RK, Ganesa S, Vasquez JC, Bindra RS. Targeting IDH1\/2 mutant cancers with combinations of ATR and PARP inhibitors. NAR Cancer. 2021;3(2):zcab018.","journal-title":"NAR Cancer."},{"issue":"8","key":"1863_CR72","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11912-021-01077-z","volume":"23","author":"KB Elmore","year":"2021","unstructured":"Elmore KB, Schaff LR. DNA repair mechanisms and therapeutic targets in glioma. Curr Oncol Rep. 2021;23(8):87.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"1863_CR73","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1038\/s41467-023-36878-2","volume":"14","author":"C Dmello","year":"2023","unstructured":"Dmello C, Zhao J, Chen L, Gould A, Castro B, Arrieta VA, et al. Checkpoint kinase 1\/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade. Nat Commun. 2023;14(1):1566.","journal-title":"Nat Commun"},{"issue":"6","key":"1863_CR74","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1177\/1778.19292","volume":"100","author":"F Wang","year":"2014","unstructured":"Wang F, Luo Y, Li C, Chen L. Correlation between deregulated expression of PER2 gene and degree of glioma malignancy. Tumori. 2014;100(6):e266\u201372.","journal-title":"Tumori"},{"key":"1863_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.656981","volume":"9","author":"Q Li","year":"2021","unstructured":"Li Q, Xia D, Wang Z, Liu B, Zhang J, Peng P, et al. Circadian rhythm gene PER3 negatively regulates stemness of prostate cancer stem cells via WNT\/beta-catenin signaling in tumor microenvironment. Front Cell Dev Biol. 2021;9: 656981.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1863_CR76","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41467-019-08886-8","volume":"10","author":"JN Bianco","year":"2019","unstructured":"Bianco JN, Bergoglio V, Lin YL, Pillaire MJ, Schmitz AL, Gilhodes J, et al. Overexpression of Claspin and timeless protects cancer cells from replication stress in a checkpoint-independent manner. Nat Commun. 2019;10(1):910.","journal-title":"Nat Commun"},{"issue":"6","key":"1863_CR77","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.4049\/jimmunol.167.6.3463","volume":"167","author":"W Sato","year":"2001","unstructured":"Sato W, Kadomatsu K, Yuzawa Y, Muramatsu H, Hotta N, Matsuo S, et al. Midkine is involved in neutrophil infiltration into the tubulointerstitium in ischemic renal injury. J Immunol. 2001;167(6):3463\u20139.","journal-title":"J Immunol"},{"issue":"18","key":"1863_CR78","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1089\/ars.2021.0153","volume":"35","author":"J Hinterdobler","year":"2021","unstructured":"Hinterdobler J, Schunkert H, Kessler T, Sager HB. Impact of acute and chronic psychosocial stress on vascular inflammation. Antioxid Redox Signal. 2021;35(18):1531\u201350.","journal-title":"Antioxid Redox Signal"},{"issue":"5","key":"1863_CR79","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1182\/blood-2005-11-011932","volume":"108","author":"C Shah","year":"2006","unstructured":"Shah C, Hari-Dass R, Raynes JG. Serum amyloid A is an innate immune opsonin for Gram-negative bacteria. Blood. 2006;108(5):1751\u20137.","journal-title":"Blood"},{"issue":"3","key":"1863_CR80","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11060-017-2386-z","volume":"132","author":"FH Knebel","year":"2017","unstructured":"Knebel FH, Uno M, Galatro TF, Belle LP, Oba-Shinjo SM, Marie SKN, et al. Serum amyloid A1 is upregulated in human glioblastoma. J Neurooncol. 2017;132(3):383\u201391.","journal-title":"J Neurooncol"},{"issue":"5","key":"1863_CR81","doi-asserted-by":"publisher","first-page":"428","DOI":"10.5662\/wjm.v12.i5.428","volume":"12","author":"M Singh","year":"2022","unstructured":"Singh M, Raghav A, Gautam KA. Role of the circulatory interleukin-6 in the pathogenesis of gliomas: a systematic review. World J Methodol. 2022;12(5):428\u201337.","journal-title":"World J Methodol"},{"issue":"1","key":"1863_CR82","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4049\/jimmunol.166.1.121","volume":"166","author":"MR Graf","year":"2001","unstructured":"Graf MR, Prins RM, Merchant RE. IL-6 secretion by a rat T9 glioma clone induces a neutrophil-dependent antitumor response with resultant cellular, antiglioma immunity. J Immunol. 2001;166(1):121\u20139.","journal-title":"J Immunol"},{"key":"1863_CR83","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw5680","author":"EA Chiocca","year":"2019","unstructured":"Chiocca EA, Yu JS, Lukas RV, Solomon IH, Ligon KL, Nakashima H, et al. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aaw5680.","journal-title":"Sci Transl Med."},{"key":"1863_CR84","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136417","author":"M Yarchoan","year":"2020","unstructured":"Yarchoan M, Ho WJ, Mohan A, Shah Y, Vithayathil T, Leatherman J, et al. Effects of B cell-activating factor on tumor immunity. JCI Insight. 2020. https:\/\/doi.org\/10.1172\/jci.insight.136417.","journal-title":"JCI Insight."},{"issue":"2","key":"1863_CR85","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/0008-5472.CAN-21-1171","volume":"82","author":"W Liu","year":"2022","unstructured":"Liu W, Stachura P, Xu HC, Varaljai R, Shinde P, Ganesh NU, et al. BAFF attenuates immunosuppressive monocytes in the melanoma tumor microenvironment. Cancer Res. 2022;82(2):264\u201377.","journal-title":"Cancer Res"},{"issue":"11","key":"1863_CR86","doi-asserted-by":"publisher","first-page":"4736","DOI":"10.1111\/cas.15141","volume":"112","author":"S Yamamuro","year":"2021","unstructured":"Yamamuro S, Takahashi M, Satomi K, Sasaki N, Kobayashi T, Uchida E, et al. Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance. Cancer Sci. 2021;112(11):4736\u201347.","journal-title":"Cancer Sci"},{"issue":"1","key":"1863_CR87","first-page":"vdaa082","volume":"2","author":"I Alnahhas","year":"2020","unstructured":"Alnahhas I, Alsawas M, Rayi A, Palmer JD, Raval R, Ong S, et al. Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. Neurooncol Adv. 2020;2(1):vdaa082.","journal-title":"Neurooncol Adv."},{"issue":"1","key":"1863_CR88","doi-asserted-by":"publisher","first-page":"354","DOI":"10.7150\/jca.63595","volume":"13","author":"D Liu","year":"2022","unstructured":"Liu D, Yang T, Ma W, Wang Y. Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation. J Cancer. 2022;13(1):354\u201363.","journal-title":"J Cancer"},{"issue":"21","key":"1863_CR89","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.18632\/oncotarget.28090","volume":"12","author":"LH El Touny","year":"2021","unstructured":"El Touny LH, Hose C, Connelly J, Harris E, Monks A, Dull AB, et al. ATR inhibition reverses the resistance of homologous recombination deficient MGMTlow\/MMRproficient cancer cells to temozolomide. Oncotarget. 2021;12(21):2114\u201330.","journal-title":"Oncotarget"},{"issue":"12","key":"1863_CR90","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1111\/cns.13966","volume":"28","author":"Z Wang","year":"2022","unstructured":"Wang Z, Chen G. Insights about circadian clock in glioma: from molecular pathways to therapeutic drugs. CNS Neurosci Ther. 2022;28(12):1930\u201341.","journal-title":"CNS Neurosci Ther"},{"key":"1863_CR91","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-neuro-100322-112249","volume":"46","author":"MH Hastings","year":"2023","unstructured":"Hastings MH, Brancaccio M, Gonzalez-Aponte MF, Herzog ED. Circadian rhythms and astrocytes: the good, the bad, and the ugly. Annu Rev Neurosci. 2023;46:123\u201343.","journal-title":"Annu Rev Neurosci"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01863-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-01863-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01863-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T22:58:42Z","timestamp":1738796322000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-01863-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1863"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-01863-2","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"5 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}